表紙
市場調査レポート

網膜変性:パイプライン製品の分析

Retinal Degeneration - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 257837
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
網膜変性:パイプライン製品の分析 Retinal Degeneration - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 84 Pages
概要

網膜変性疾患には、眼球に作用する多種多様な種類の症状・異常が含まれています。主な症状として、視野のゆがみや、色覚異常(色がぼやける・暗くなる)、突然の暗点・盲点の出現などが挙げられます。疾病素質には、年齢や喫煙、肥満、高血圧、炎症、心血管疾患などがあります。

当レポートでは、世界各国での網膜変性治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

網膜変性の概要

治療薬の開発

  • 網膜変性向けパイプライン製品:概要
  • 網膜変性向けパイプライン製品:比較分析

各企業で開発中の網膜変性治療薬

大学/研究機関で研究中の網膜変性治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

網膜変性治療薬:開発中の製品の一覧(企業別)

網膜変性治療薬:研究中の製品の一覧(大学/研究機関別)

網膜変性治療薬の開発に従事している企業

  • AmpliPhi Biosciences Corporation
  • SanBio, Inc.
  • to-BBB technologies BV
  • Aprogen, Inc.
  • X-BODY BioSciences, Inc.
  • GenSight Biologics
  • Spark Therapeutics, Inc.

網膜変性:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • tgAAG76
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • SB-623
  • AP-202
  • 環状ヌクレオチドのアナログ(類似体)
  • 網膜色素変性向け小分子8
  • SNC-121
  • 全脈絡膜萎縮向け遺伝治療法
  • 網膜変性症向け遺伝子療法
  • CB-11
  • S-Allymercapto-N-Acetylcysteine
  • XB-2202

網膜変性治療薬:パイプライン製品の最新動向

網膜変性治療薬:開発が休止状態の製品

網膜変性関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全5件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7464IDB

Summary

Global Markets Direct's, 'Retinal Degeneration - Pipeline Review, H2 2015', provides an overview of the Retinal Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Retinal Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinal Degeneration Overview
  • Therapeutics Development
    • Pipeline Products for Retinal Degeneration - Overview
    • Pipeline Products for Retinal Degeneration - Comparative Analysis
  • Retinal Degeneration - Therapeutics under Development by Companies
  • Retinal Degeneration - Therapeutics under Investigation by Universities/Institutes
  • Retinal Degeneration - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Retinal Degeneration - Products under Development by Companies
  • Retinal Degeneration - Products under Investigation by Universities/Institutes
  • Retinal Degeneration - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • Alkeus Pharmaceuticals, Inc.
    • Applied Genetic Technologies Corporation
    • Bionature E.A. Ltd.
    • Biovista Inc.
    • GenSight Biologics SA
    • SanBio, Inc.
    • Santhera Pharmaceuticals Holding AG
    • Senju Pharmaceutical Co., Ltd.
  • Retinal Degeneration - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BVA-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVA-203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNS-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for X-linked retinoschisis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-010 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-011 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • idebenone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KH-176 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MTP-131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-623 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inherited Retinal Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNJ-1945 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Retinal Degeneration - Recent Pipeline Updates
  • Retinal Degeneration - Dormant Projects
  • Retinal Degeneration - Product Development Milestones
    • Featured News & Press Releases
      • Jun 26, 2015: CHMP recommends granting a marketing authorization for Santhera's Raxone for the treatment of Leber's Hereditary Optic Neuropathy
      • Jun 05, 2014: European Medicines Agency Validates Santhera's Marketing Authorization Application for Raxone in Leber's Hereditary Optic Neuropathy
      • May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON
      • Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy
      • Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France
      • Jul 11, 2013: Santhera Initiates Collaboration with the European Vision Institute Clinical Research Network in LHON
      • Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application for Raxone In LHON
      • Jan 18, 2013: Santhera Pharma Receives Negative Opinion from EMA's CHMP On Marketing Authorization Application For Raxone
      • Nov 16, 2012: Santhera Pharma Expects CHMP Opinion on MAA for Raxone In Early 2013
      • Jul 26, 2011: Catena Improves Sight for Patients With Inherited Blindness, Newcastle University Study Finds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinal Degeneration, H2 2015
  • Number of Products under Development for Retinal Degeneration - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Retinal Degeneration - Pipeline by 2-BBB Medicines BV, H2 2015
  • Retinal Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2015
  • Retinal Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2015
  • Retinal Degeneration - Pipeline by Bionature E.A. Ltd., H2 2015
  • Retinal Degeneration - Pipeline by Biovista Inc., H2 2015
  • Retinal Degeneration - Pipeline by GenSight Biologics SA, H2 2015
  • Retinal Degeneration - Pipeline by SanBio, Inc., H2 2015
  • Retinal Degeneration - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2015
  • Retinal Degeneration - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Retinal Degeneration Therapeutics - Recent Pipeline Updates, H2 2015
  • Retinal Degeneration - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Retinal Degeneration, H2 2015
  • Number of Products under Development for Retinal Degeneration - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top